, Volume 68, Issue 1, pp 123–130 | Cite as

Diclofenac Sodium Injection (Dyloject®)

In Postoperative Pain
Adis Drug Profile


  • ▲ A new formulation of the nonselective NSAID diclofenac sodium suitable for intravenous bolus injection has been developed using hydroxypropyl β-cyclodextrin as a solubility enhancer (HPβCD diclofenac).

  • ▲ HPβCD diclofenac intravenous bolus injection was shown to be bioequivalent to the existing parenteral formulation of diclofenac containing propylene glycol and benzyl alcohol as solubilizers (PG-BA diclofenac), which is relatively insoluble and requires slow intravenous infusion over 30 minutes.

  • ▲ Single-dose HPβCD diclofenac 3.75, 9.4, 18.75, 25, 37.5, 50 and 75 mg administered by intravenous bolus injection produced significantly greater responses than placebo for total pain relief (TOTPAR) over 6 hours or pain intensity at 4 hours in the treatment of moderate or severe postoperative dental pain in randomized, double-blind trials. HPβCD diclofenac 37.5 and 75 mg were similar in efficacy to intravenous bolus ketorolac 30 mg.

  • ▲ In a well controlled trial, single-dose HPβCD diclofenac 75 mg intravenous bolus injection was shown to be superior to PG-BA diclofenac 75 mg intravenous infusion with respect to TOTPAR over 4 hours, indicating faster onset of analgesia in the treatment of moderate or severe postoperative dental pain. Both HPβCD diclofenac and PG-BA diclofenac were superior to placebo.

  • ▲ HPβCD diclofenac was generally well tolerated during single-dose treatment of postoperative pain. The tolerability profile was similar to that of PG-BA diclofenac, but with a lower incidence of thrombophlebitis.


Pain Intensity Ketorolac Thrombophlebitis Intramuscular Administration Intravenous Bolus Injection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    White PF. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg 2002; 94: 577–85PubMedCrossRefGoogle Scholar
  2. 2.
    Filos KS, Lehmann KA. Current concepts and practice in postoperative pain management: need for a change? Eur Surg Res 1999; 31(2): 97–107PubMedCrossRefGoogle Scholar
  3. 3.
    Wheeler M, Oderda GM, Ashburn MA, et al. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain 2002 Jun; 3(3): 159–80PubMedCrossRefGoogle Scholar
  4. 4.
    National Pharmaceutical Council. Pain: current understanding of assessment, management, and treatments [online]. Available from URL: [Accessed 2007 Jun 5]
  5. 5.
    Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988 Mar; 35(3): 244–85PubMedCrossRefGoogle Scholar
  6. 6.
    Barden J, Edwards J, Moore RA, et al. Single dose oral diclofenac for postoperative pain. Cochrane Database Syst Rev 2004; (2): CD004768Google Scholar
  7. 7.
    Leeson RM, Harrison S, Ernst CC, et al. Dyloject, a novel injectable diclofenac formulation, offers greater safety and efficacy than Voltarol for postoperative dental pain. Reg Anesth Pain Med 2007 Jul–Aug; 32(4): 303–10PubMedGoogle Scholar
  8. 8.
    Brogden RN, Heel RC, Pakes GE, et al. Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. Drugs 1980 Jul; 20(1): 24–48PubMedCrossRefGoogle Scholar
  9. 9.
    Maier R, Menasse R, Riesterer L, et al. The pharmacology of diclofenac sodium (Voltarol). Rheumatol Rehabil 1979; Suppl. 2: 11–21PubMedGoogle Scholar
  10. 10.
    Chandrasekharan NV, Dai H, Roos KLT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002 Oct 15; 99(21): 13926–31PubMedCrossRefGoogle Scholar
  11. 11.
    Javelin Pharmaceuticals Inc. A phase 1, randomized, analytically blind, fasted, single-dose, four-way crossover study of the bioavailability of one dose level of parenteral DIC075V (diclofenac sodium 75 mg/2 ml), administered intramuscularly and intravenously, vs. parenteral Voltarol® (diclofenac sodium 75 mg/3 ml) administered intramuscularly and intravenously in healthy adult volunteers. New York: Javelin Pharmaceuticals Inc., 2004. (Data on file)Google Scholar
  12. 12.
    Christensen K, Daniels S, Bandy D, et al. Dyloject™, a novel injectable diclofenac: efficacy of unexpectedly low doses and faster onset than ketorolac [abstract no. 643]. Eur J Pain 2006; 10 Suppl. S1: S168CrossRefGoogle Scholar
  13. 13.
    Javelin Pharmaceuticals Inc. A randomized, double-blind, placebo- and comparator-controlled, single-dose, parallel-group comparison of the analgesic efficacy and safety of intravenous DIC075V (diclofenac sodium injection), ketorolac tromethamine and placebo following surgery. New York: Javelin Pharmaceuticals Inc., 2006. (Data on file)Google Scholar
  14. 14.
    Data on file, Javelin Pharmaceuticals Inc., 2007Google Scholar
  15. 15.
    Wallerstein K. A cost minimization analysis of IV bolus versus IV infusion diclofenac in post-operative pain [abstract and poster]. 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2007 Oct 20–23; DublinGoogle Scholar
  16. 16.
    Catalano MA. Worldwide safety experience with diclofenac. Am J Med 1986 Apr 28; 80(4B): 81–7PubMedCrossRefGoogle Scholar
  17. 17.
    Novartis Pharmaceuticals UK Ltd. Voltarol ampoules: summary of product characteristics [online]. Available from URL: [Accessed 2007 May 30]
  18. 18.
    Javelin Pharmaceuticals Inc. Javelin Pharmaceuticals receives marketing authorization approval for Dyloject® in the United Kingdom [media release]. 2007 Oct 31Google Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore 0754, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations